|
|
|
|
|
|
|
 Fluvoxamine (Luvox®) is a well-known and trusted anti-depressant that has been prescribed to almost 30 million people worldwide. The product is not only used in depression but also for obsessive compulsive disorder (OCD). Luvox® is a product from Solvay Pharmaceuticals’ innovative research.
In 1983 it was the first of the now hugely popular class of Selective Serotonin Reuptake Inhibitors (SSRI) to reach the market. It is specially designed to increase the concentration of serotonin in the brain. When the amount of serotonin is increased, the symptoms of the depression will start to disappear.
Serotonin is a neurotransmitter which particularly influences the regulation of emotions. It is believed to play an important part of the biochemistry of mental disorders like depression and anxiety.
Luvox® was the first SSRI to enter the Japanese market for both the depression and OCD indication. In Japan this mental health drug was co-developed by Solvay and Meiji Seika. Introduction in Japan took place in May 1999, under the trade name Luvox® by Astellas Pharma and Solvay Seiyaku (the Japanese fully-owned subsidiary of Solvay Pharmaceuticals) as well as under the trademark Depromel® by Meiji Seika. In Japan, a new indication for Social Anxiety Disorder (SAD), was granted for Luvox in 2005.
|
|
|
|
|
|
